Sobin LH, Gospodarowicz MK, Wittekind C, eds. International Union Against Cancer. TNM classification of malignant tumours. 7th ed. New York: Wiley-Blackwell; 2010.
Ettinger DS, Akerley W, Borghaei H. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 2, 2012. Available at: http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed October 4, 2011.
Raz DJ, Lanuti M, Gaissert HC. Outcomes of patients with isolated adrenal metastasis from non-small cell lung carcinoma. Ann Thorac Surg 2011;92:1788–1793.
Khan AJ, Mehta PS, Zusag TW. Long term disease-free survival resulting from combined modality management of patients presenting with oligometastatic, non-small cell lung carcinoma (NSCLC). Radiother Oncol 2006;81:163–167.
Yano T, Haro A, Yoshida T. Prognostic impact of local treatment against postoperative oligometastases in non-small cell lung cancer. J Surg Oncol 2010;102:852–855.
Matthews MJ, Kanhouwa S, Pickren J, Robinette D. Frequency of residual and metastatic tumor in patients undergoing curative surgical resection for lung cancer. Cancer Chemother Rep 3 1973;4:63–67.
Ettinghausen SE, Burt ME. Prospective evaluation of unilateral adrenal masses in patients with operable non-small-cell lung cancer. J Clin Oncol 1991;9:1462–1466.
Reed CE, Harpole DH, Posther KE. Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer. J Thorac Cardiovasc Surg 2003;126:1943–1951.
Downey RJ, Ng KK, Kris MG. A phase II trial of chemotherapy and surgery for non-small cell lung cancer patients with a synchronous solitary metastasis. Lung Cancer 2002;38:193–197.
Beitler AL, Urschel JD, Velagapudi SR, Takita H. Surgical management of adrenal metastases from lung cancer. J Surg Oncol 1998;69:54–57.
Porte H, Siat J, Guibert B. Resection of adrenal metastases from non-small cell lung cancer: a multicenter study. Ann Thorac Surg 2001;71:981–985.
Tanvetyanon T, Robinson LA, Schell MJ. Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis. J Clin Oncol 2008;26:1142–1147.
Mordant P, Arame A, De Dominicis F. Which metastasis management allows long-term survival of synchronous solitary M1b non-small cell lung cancer? Eur J Cardiothorac Surg, in press.
De Pas TM, de Braud F, Catalano G. Oligometastatic non-small cell lung cancer: a multidisciplinary approach in the positron emission tomographic scan era. Ann Thorac Surg 2007;83:231–234.
Dahele M, Senan S. The role of stereotactic ablative radiotherapy for early-stage and oligometastatic non-small cell lung cancer: evidence for changing paradigms. Cancer Res Treat 2011;43:75–82.
Pao W, Miller V, Zakowski M. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004;101:13306–13311.
Shigematsu H, Lin L, Takahashi T. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339–346.
Rudin CM, Avila-Tang E, Harris CC. Lung cancer in never smokers: molecular profiles and therapeutic implications. Clin Cancer Res 2009;15:5646–5661.
Scagliotti GV, Parikh P, von Pawel J. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543–3551.